Loading...
4Front Ventures Corp.
FFNT.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.005
CA$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $20.98M in Q4 2023 to $17.13M in Q3 2024. Gross profit continued to perform well, with margins at 21% in the latest quarter. Operating income reached -$6.51M in Q3 2024, holding a steady -38% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$3.28M. Net income dropped to -$6.40M, keeping EPS at -$0.007. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan